
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded oral liquid containing amlodipine besylate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing amlodipine are listed in tablet, solution and suspension forms, and in capsule form only in combination with another active ingredient.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Amlodipine besylate is a calcium channel blocker taken by mouth that pharmacies may compound, including as an oral suspension, on a prescriber's order.
Amlodipine besylate is the besylate salt of amlodipine, a long-acting calcium channel blocker of the dihydropyridine type. It blocks calcium from entering the muscle cells of blood vessel walls and the heart, with a greater effect on blood vessels, letting vessels relax. Manufactured products include Norvasc tablets and Norliqva oral solution, both amlodipine besylate under NDAs. Their labels list treatment of high blood pressure, to lower blood pressure, and coronary artery disease, including chronic stable angina, vasospastic (Prinzmetal's or variant) angina, and angiographically documented coronary artery disease in patients without heart failure or an ejection fraction under 40%. A prescriber might order amlodipine compounded as an oral liquid for a child or an older patient who has trouble swallowing tablets, or in a strength or form that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Amlodipine labels carry no boxed warning. Do not take it if you are allergic to amlodipine. Low blood pressure with symptoms can occur, particularly in people with severe aortic stenosis (a narrowed heart valve). After starting amlodipine or raising the dose, chest pain can get worse or a heart attack can occur, particularly in people with severe blockage of the heart arteries; get emergency care for worsening chest pain, a fast or irregular heartbeat, or fainting. Swelling (edema) is the label's most common side effect. Medicines that block the liver enzyme CYP3A can raise amlodipine levels, amlodipine can raise levels of simvastatin, cyclosporine and tacrolimus, and use with sildenafil calls for watching for low blood pressure. The Norvasc label says pregnancy data are too limited to show a drug risk; LactMed says needing amlodipine is not a reason to stop breastfeeding. Talk to your prescriber or pharmacist about side effects.
Amlodipine is a dihydropyridine calcium antagonist that inhibits transmembrane calcium influx into vascular smooth muscle and cardiac muscle, with a greater effect on vascular smooth muscle (Norvasc label). Oral PK: peak plasma concentrations at 6 to 12 hours; absolute bioavailability 64 to 90%, not altered by food; about 90% hepatic conversion to inactive metabolites; about 93% protein bound; terminal half-life about 30 to 50 hours, 56 hours in hepatic impairment; not significantly influenced by renal impairment. Labeled indications (Norvasc tablets; Norliqva oral solution): hypertension, including patients 6 years and older, chronic stable angina, vasospastic angina, and angiographically documented coronary artery disease without heart failure or an ejection fraction under 40%. Stability data exist for compounded amlodipine besylate oral suspensions prepared from commercial tablets (Friciu et al., Can J Hosp Pharm 2016). StatPearls lists Raynaud phenomenon and group 1 pulmonary arterial hypertension as off-label uses; these are not FDA-approved indications. Titrate slowly in severe hepatic impairment. Monitor for hypotension and edema with moderate or strong CYP3A inhibitors, blood pressure with CYP3A inducers, and cyclosporine or tacrolimus troughs; limit simvastatin per label. Dosing is per prescriber. Measure blood pressure regularly; StatPearls notes routine labs are generally unnecessary.
Shake the bottle if your label says to. Measure each dose with the oral syringe or dosing cup the pharmacy gave you, never a kitchen spoon. Give the liquid slowly into the mouth. Rinse the syringe with water after each use. Call the pharmacy if you are unsure how to measure.
Storage depends on the vehicle. Water-based liquids with a preservative usually carry a USP <795> beyond-use date of up to 35 days; without a preservative they are kept refrigerated for up to 14 days. Oil-based (nonaqueous) oral liquids may carry up to 90 days. Your label states whether to refrigerate and the beyond-use date. Keep out of reach of children and discard after that date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take orally